Cita APA

JR, S., P, D., J, P., F, G., A, I., H, V., . . . R, P. (2023). A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.

Citación estilo Chicago

JR, Santos, et al. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat As a Switch Strategy in HIV-1-Infected Patients With Resistance to At Least 2 Antiretroviral Classes. 2023.

Cita MLA

JR, Santos, et al. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat As a Switch Strategy in HIV-1-Infected Patients With Resistance to At Least 2 Antiretroviral Classes. 2023.